R&D News | pharmaphorum

News

Janssen adds Hemera's AMD gene therapy to pipeline

Johnson & Johnson’s pharma unit Janssen has bought rights to an investigational gene therapy for a severe form age-related macular degeneration from specialist biotech Hemera Bioscience

News

PureTech begins trial of potential 'Long COVID' drug as case...

As the pandemic drags on there are increasing concerns about “Long COVID” – where symptoms persist long after the initial infection has been fought off.

News

Pills spilling out of a prescription bottle on 100 dollar paper currency

Swiss start-up Noema raises $59m to develop neurology drugs ...

Swiss biotech Noema has raised 54 million Swiss francs ($59m) to develop four neurological disorder drugs licensed in from Roche.

News

Pfizer/BioNTech say COVID-19 vaccine could be approved in Eu...

Pfizer and BioNTech have filed their COVID-19 vaccine with the European medicines regulator, paving the way for a potential approval before the end of the year.

News

Closeup of X-ray photography of human brain

Eisai forges CNS alliance with UK’s Wren Therapeutics

Japanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for neurodegenerative disorders.

News

Biogen bulks up pipeline with Sage drugs in $3bn deal

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs f

Janssen adds Hemera's AMD gene therapy to pipeline

PureTech begins trial of potential 'Long COVID' drug as case...

Swiss start-up Noema raises $59m to develop neurology drugs ...

Pfizer/BioNTech say COVID-19 vaccine could be approved in Eu...

Eisai forges CNS alliance with UK’s Wren Therapeutics

Biogen bulks up pipeline with Sage drugs in $3bn deal

Hengrui gets world-first okay for platelet drug hetrombopag

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks